Here are the 10-K annual reports from Immuneering Corporation (IMRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMRX filings page.
Immuneering Corporation is a late-stage clinical oncology company developing Deep Cyclic Inhibitors, a new class of targeted cancer drugs designed to intermittently block tumor signaling while sparing healthy cells.
Lead candidate atebimetinib (IMM-1-104), an oral MEK inhibitor, is moving toward a global Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic ductal adenocarcinoma, with about 510 patients planned and first dosing expected in mid-2026. Positive Phase 1/2a data in pancreatic cancer showed encouraging survival and tolerability, and the drug holds FDA Fast Track and orphan designations for pancreatic cancer and Fast Track for NRAS-mutant melanoma.
Second program envometinib (IMM-6-415) showed promising early PK/PD and safety but has been paused internally while partnership options are explored.
For 2025, Immuneering reported a net loss of $56.0M on operating expenses of $59.4M, mainly R&D. Significant 2025 equity offerings lifted cash, cash equivalents and marketable securities to $217.0M, which management believes can fund operations into 2029.